The FDA just put out an early alert that's getting attention in the medical device world. Integra LifeSciences Holdings Corporation (IART) is dealing with a potentially serious problem involving some of its wound and burn care products, and the issue comes down to something that sounds deceptively simple but matters enormously: packaging and production failures that could let infections sneak in.

What Products Are We Talking About?

According to the FDA, Integra has already reached out to affected customers with a clear message—pull all MediHoney Wound and Burn products from use, along with certain lots of CVS Wound Gel. These products are workhorses in wound care, commonly used to treat burns and wounds by maintaining a moist environment, protecting skin from further irritation and breakdown, and generally helping things heal the way they're supposed to. The FDA says it'll keep updating the public as more information comes in.

The Core Problem

Here's what went wrong. Integra identified packaging failures in its MediHoney Wound and Burn products that could compromise the sterile barrier. That's a big deal because if the sterile barrier is breached, you're basically opening the door to infection—exactly what you don't want when treating vulnerable wounds. In some cases, the packaging failures could also make the product unusable entirely, which means delays in care when time matters.

The FDA noted that if affected products were already used and standard care protocols were followed, no additional patient follow-up is necessary. That's a small relief, at least.

For the CVS Wound Gel products, the issue is slightly different but equally concerning. Integra reported production and process control problems that could also create infection risks if the products are used. Same story with packaging failures potentially preventing the device from working as intended.

Injuries and Response

As of December 19, 2025, Integra has reported 11 serious injuries linked to the MediHoney products and three serious injuries tied to the CVS Wound Gel. No deaths have been reported, which is obviously good news, but 14 serious injuries is nothing to shrug off.

The FDA's advice to healthcare providers and users is straightforward: stop using affected products immediately and get them out of circulation. On January 16, Integra sent letters to customers outlining the game plan—quarantine impacted units, notify clinical staff, discard expired products following facility procedures, and make absolutely sure recalled items don't get used.

Distributors got their own set of marching orders: halt distribution, notify customers, collect response forms and affected products, and handle customer communications directly. Integra is routing end users back to distributors for help navigating the recall.

IART Price Action: Integra LifeSciences shares were down 1.89% at $11.96 at the time of publication on Friday, according to market data.